FibroBiologics, Inc. Common Stock
FBLGHealthcare|Biotechnology|US
$0.98
+0.02 (+2.39%)
DCF Value
$0.73
Tangible Book / Share
$1.23
Cash / Share
$0.93
About
FibroBiologics, Inc. operates as a clinical-stage biopharmaceutical firm, advancing therapies derived from fibroblasts toward commercialization within the United States. The company's pipeline includes CybroCell, currently being developed to address degenerative disc disease; CYMS101, targeting multiple sclerosis; and CYWC628 for wound repair. Further demonstrating its broad scope, early-stage investigations are underway for CYTER915, aimed at restoring or enhancing thymus and/or spleen function; CYPS317, for psoriasis; and TCB190, designed to combat specific cancers. FibroBiologics was founded in 2021 and is situated in Houston, Texas.
Stock Price
-85.4%(1Y)
1M
-11.7%
3M
+0.3%
6M
-15.6%
YTD
-78.2%
1Y
-86.3%
3Y
-99.8%
5Y
-99.8%
Pipeline Summary
0 total trials0
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
Key Facts
Market Cap$6.5M
Employees15 (+15% YoY)
CEOPeter O'Heeron
IPO DateFeb 1, 2024
Beta1.22
52-Week Range$0.62 – $9.6
Avg Volume172,851
ExchangeNASDAQ
Websitefibrobiologics.com
Ownership
Float78.0%
Shares Outstanding6.7M
Recent Insider Trades
Khoja HamidAWARD
Sep 15, 2026298,508 shares @ $1.68
Khoja HamidAWARD
Sep 15, 2026298,508 shares @ $1.55
Steinberg LeighOTHER
Aug 20, 20260 shares
Rubins Kathleen HalliseyOTHER
Jul 8, 2026562 shares @ $65.60
Hoffman Robert E.AWARD
Jun 23, 202630,803 shares @ $0.75
Peers
Recent News
FibroBiologics Announces Grant of European Patent for Fibroblast Delivery of Tumor Inhibitory Agents
Nov 5, 2026 · prnewswire.com
FibroBiologics Presents Preclinical Data on Fibroblast Spheroid-Derived Chondrocyte Spheroids for Degenerative Disc Disease at the North American Spine Society 2026 Annual Meeting
Oct 19, 2026 · prnewswire.com
FibroBiologics Announces Australian Patent Accepted for Cellular Blend for the Regeneration of Chondrocytes and Cartilage Cells in Degenerated Spinal Discs
Oct 14, 2026 · prnewswire.com
FibroBiologics Files Patent Application for Technology Designed to Produce GLP-1 and Other Therapeutic Peptides Inside the Body
Oct 7, 2026 · prnewswire.com
FibroBiologics Announces Grant of European Patent for Methods of Enhancing Fibroblast Therapeutic Activity
Sep 29, 2026 · prnewswire.com
Data last updated: Nov 9, 2026, 04:10 AM